Shares of Immunomedics were under pressure yesterday due to management comments on outstanding review issues for the Biologics License Application for sacituzumab govitecan in triple negative breast cancer, Wells Fargo analyst Jim Birchenough tells investors in a research note. The analyst spoke with management and understands that outstanding questions "are in line with that expected in the normal course of a BLA review." Further, experience suggests that absence of interaction before a PDUFA is a bad sign and that increased interaction, as appears to be the case here, is positive, says Birchenough. The analyst remains confident in the prospects for a timely approval and would be buyers of Immunomedics shares on the weakness.